Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 2
2004 1
2005 5
2007 3
2008 6
2009 5
2010 8
2011 2
2012 7
2013 6
2014 6
2015 4
2016 5
2017 5
2018 8
2019 3
2020 6
2021 5
2022 5
2023 5
2024 5
2025 2

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
A human neural crest model reveals the developmental impact of neuroblastoma-associated chromosomal aberrations.
Saldana-Guerrero IM, Montano-Gutierrez LF, Boswell K, Hafemeister C, Poon E, Shaw LE, Stavish D, Lea RA, Wernig-Zorc S, Bozsaky E, Fetahu IS, Zoescher P, Pötschger U, Bernkopf M, Wenninger-Weinzierl A, Sturtzel C, Souilhol C, Tarelli S, Shoeb MR, Bozatzi P, Rados M, Guarini M, Buri MC, Weninger W, Putz EM, Huang M, Ladenstein R, Andrews PW, Barbaric I, Cresswell GD, Bryant HE, Distel M, Chesler L, Taschner-Mandl S, Farlik M, Tsakiridis A, Halbritter F. Saldana-Guerrero IM, et al. Among authors: potschger u. Nat Commun. 2024 May 3;15(1):3745. doi: 10.1038/s41467-024-47945-7. Nat Commun. 2024. PMID: 38702304 Free PMC article.
Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.
Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Yaniv I, Laureys G, Brock P, Michon JM, Owens C, Trahair T, Chan GCF, Ruud E, Schroeder H, Beck Popovic M, Schreier G, Loibner H, Ambros P, Holmes K, Castellani MR, Gaze MN, Garaventa A, Pearson ADJ, Lode HN. Ladenstein R, et al. Among authors: potschger u. Lancet Oncol. 2018 Dec;19(12):1617-1629. doi: 10.1016/S1470-2045(18)30578-3. Epub 2018 Nov 12. Lancet Oncol. 2018. PMID: 30442501 Clinical Trial.
Risk factors in DUX4-positive childhood and adolescent B-cell acute lymphoblastic leukemia.
Schinnerl D, Riebler M, Schumich A, Haslinger S, Bramböck A, Inthal A, Nykiel M, Maurer-Granofszky M, Haas OA, Pötschger U, Köhrer S, Nebral K, Dworzak MN, Attarbaschi A, Strehl S. Schinnerl D, et al. Among authors: potschger u. Blood Cancer J. 2024 Jul 22;14(1):119. doi: 10.1038/s41408-024-01099-3. Blood Cancer J. 2024. PMID: 39039054 Free PMC article.
Low rate of nonrelapse mortality in under-4-year-olds with ALL given chemotherapeutic conditioning for HSCT: a phase 3 FORUM study.
Bader P, Pötschger U, Dalle JH, Moser LM, Balduzzi A, Ansari M, Buechner J, Güngör T, Ifversen M, Krivan G, Pichler H, Renard M, Staciuk R, Sedlacek P, Stein J, Heusel JR, Truong T, Wachowiak J, Yesilipek A, Locatelli F, Peters C. Bader P, et al. Among authors: potschger u. Blood Adv. 2024 Jan 23;8(2):416-428. doi: 10.1182/bloodadvances.2023010591. Blood Adv. 2024. PMID: 37738088 Free PMC article. Clinical Trial.
Comparable outcomes after busulfan- or treosulfan-based conditioning for allo-HSCT in children with ALL: results of FORUM.
Kalwak K, Moser LM, Pötschger U, Bader P, Kleinschmidt K, Meisel R, Dalle JH, Yesilipek A, Balduzzi A, Krivan G, Goussetis E, Staciuk R, Sedlacek P, Pichler H, Svec P, Gabriel M, Güngör T, Bilic E, Buechner J, Renard M, Vettenranta K, Ifversen M, Diaz-de-Heredia C, Stein J, Toporski J, Bierings M, Peters C, Ansari M, Locatelli F. Kalwak K, et al. Among authors: potschger u. Blood Adv. 2025 Feb 25;9(4):741-751. doi: 10.1182/bloodadvances.2024014548. Blood Adv. 2025. PMID: 39602342 Free PMC article.
Reproducibility Analysis of Radiomic Features on T2-weighted MR Images after Processing and Segmentation Alterations in Neuroblastoma Tumors.
Veiga-Canuto D, Fernández-Patón M, Cerdà Alberich L, Jiménez Pastor A, Gomis Maya A, Carot Sierra JM, Sangüesa Nebot C, Martínez de Las Heras B, Pötschger U, Taschner-Mandl S, Neri E, Cañete A, Ladenstein R, Hero B, Alberich-Bayarri Á, Martí-Bonmatí L. Veiga-Canuto D, et al. Among authors: potschger u. Radiol Artif Intell. 2024 Jul;6(4):e230208. doi: 10.1148/ryai.230208. Radiol Artif Intell. 2024. PMID: 38864742 Free PMC article.
Clinicogenomic associations in childhood Langerhans cell histiocytosis: an international cohort study.
Kemps PG, Zondag TCE, Arnardóttir HB, Solleveld-Westerink N, Borst J, Steenwijk EC, van Egmond D, Swennenhuis JF, Stelloo E, Trambusti I, Verdijk RM, van Noesel CJM, Cleven AHG, Scheijde-Vermeulen MA, Koudijs MJ, Krsková L, Hawkins C, Egeler RM, Brok J, von Bahr Greenwood T, Svojgr K, Beishuizen A, van Laar JAM, Pötschger U, Hutter C, Sieni E, Minkov M, Abla O, van Wezel T, van den Bos C, van Halteren AGS. Kemps PG, et al. Among authors: potschger u. Blood Adv. 2023 Feb 28;7(4):664-679. doi: 10.1182/bloodadvances.2022007947. Blood Adv. 2023. PMID: 36083130 Free PMC article.
Radiological features of thymic langerhans cell histiocytosis.
Lakatos K, Herbrüggen H, Pötschger U, Prosch H, Minkov M. Lakatos K, et al. Among authors: potschger u. Pediatr Blood Cancer. 2013 Nov;60(11):E143-5. doi: 10.1002/pbc.24640. Epub 2013 Jun 29. Pediatr Blood Cancer. 2013. PMID: 23813898
88 results